AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Glucosamine Market 2020-2024: Blackmores Ltd, GNC Holdings Inc, Natures Aid Ltd & WynnPharm Inc. - ResearchAndMarkets.com

January 23, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Jan 23, 2020--

The “Glucosamine Market by Application and Geography - Forecast and Analysis 2020-2024” report has been added to ResearchAndMarkets.com’s offering.

Global Glucosamine Market: About this market

The glucosamine market analysis considers sales from both arthritis and other applications. Our study also finds the sales of glucosamine in Asia, Europe, North America, and ROW. In 2018, the arthritis segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the rising transition to nutraceuticals and dietary supplements will play a significant role in the arthritis segment to maintain its market position. Also, our global glucosamine market report looks at factors such as increasing use of combination therapy, growing popularity of e-commerce in healthcare industry, and growing geriatric population. However, limitations on variation of molecule type, wide availability of substitutes, and stringent regulations may hamper the growth of the glucosamine industry over the forecast period.

Global Glucosamine Market: Overview

Increasing the use of combination therapy

Although there are a substantial number of drugs available for the treatment of joint-related conditions, many researchers believe chronic conditions such as osteoarthritis do not respond to a monotherapy drug or a single treatment. Treatments of such conditions are most effective when given in combination. In combination therapy, nutraceutical supplements such as glucosamine are administered along with other drugs or dietary supplements such as chondroitin. Hence, the use of combination therapy will lead to the expansion of the global glucosamine market at a CAGR of over 6% during the forecast period.

Growing use of nutraceuticals in treating chronic diseases

Nutraceuticals such as glucosamine supplements are used to treat and manage various chronic diseases owing to their additional nutritional and therapeutic effects along with their health benefits and lesser side effects compared with drugs. A nutraceutical also offers physiological benefits such as protection against various chronic diseases and lifestyle disorders (obesity and cardiovascular diseases). Apart from effectively treating orthopedic conditions in combination therapy, glucosamine is also used to manage conditions such as interstitial cystitis, multiple sclerosis, and others. Vendors are also focusing on making non-animal-derived glucosamine to cater to individuals who are allergic to crustaceans and follow a kosher diet. This development is expected to have a positive impact on the overall market growth.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY APPLICATION

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

For more information about this report visit https://www.researchandmarkets.com/r/ljplzg

View source version on businesswire.com:https://www.businesswire.com/news/home/20200123005641/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/23/2020 11:55 AM/DISC: 01/23/2020 11:55 AM

http://www.businesswire.com/news/home/20200123005641/en